KBC Group NV Cuts Stake in Sarepta Therapeutics, Inc. $SRPT
KBC Group NV decreased its stake in Sarepta Therapeutics, Inc. by 98.5% in the 2nd quarter, as per its latest SEC filing. The firm now owns 3,152 shares worth $54,000. Other investors have also modified their holdings. Analysts have mixed ratings on SRPT, with a consensus target price of $33.75. Sarepta's recent earnings missed estimates, reporting a revenue of $399.36 million, down 14.5% year-over-year. Sarepta focuses on RNA-targeted therapeutics and gene therapies for rare diseases.
KBC Group NV decreased its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) by 98.5% in the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,152 shares of the biotechnology company's stock after selling 200,543 shares during the period. KBC Group NV's holdings in Sarepta Therapeutics were worth $54,000 as of its most recent SEC filing.
- Brutal 2025 for Sarepta—Analysts Still Call for 179% Upside
A number of other large investors have also modified their holdings of the stock. Ancora Advisors LLC lifted its position in Sarepta Therapeutics by 150.0% during the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company's stock worth $32,000 after acquiring an additional 300 shares in the last quarter. Banque Transatlantique SA purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $44,000. Pandora Wealth Inc. purchased a new stake in shares of Sarepta Therapeutics during the first quarter valued at approximately $45,000. Brooklyn Investment Group lifted its position in shares of Sarepta Therapeutics by 450.4% during the first quarter. Brooklyn Investment Group now owns 721 shares of the biotechnology company's stock worth $46,000 after purchasing an additional 590 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in shares of Sarepta Therapeutics by 542.3% in the second quarter. Blue Trust Inc. now owns 3,282 shares of the biotechnology company's stock valued at $56,000 after purchasing an additional 2,771 shares during the period. Institutional investors and hedge funds own 86.68% of the company's stock.
Get Sarepta Therapeutics alerts:
Analysts Set New Price Targets
SRPT has been the subject of a number of recent analyst reports. Bank of America raised their price target on shares of Sarepta Therapeutics from $16.00 to $18.00 and gave the stock an "underperform" rating in a research report on Wednesday, October 22nd. Barclays dropped their price target on Sarepta Therapeutics from $22.00 to $20.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 5th. Mizuho upgraded shares of Sarepta Therapeutics from a "neutral" rating to an "outperform" rating and lifted their price objective for the company from $19.00 to $26.00 in a research report on Wednesday, November 5th. BMO Capital Markets upgraded Sarepta Therapeutics from a "market perform" rating to an "outperform" rating and set a $50.00 price target for the company in a research report on Monday, September 22nd. Finally, William Blair reiterated an "outperform" rating on shares of Sarepta Therapeutics in a report on Tuesday, July 29th. Eight analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and six have assigned a Sell rating to the company's stock. According to MarketBeat, the company has an average rating of "Hold" and a consensus target price of $33.75.
- Sarepta Drops 42% on Fatalities; Markets Eye Solid Biosciences
View Our Latest Report on SRPT
Sarepta Therapeutics Price Performance
Shares of NASDAQ:SRPT opened at $19.35 on Wednesday. The company has a market capitalization of $2.03 billion, a PE ratio of -22.24 and a beta of 0.52. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.81 and a current ratio of 2.89. The stock has a fifty day moving average of $20.26 and a 200-day moving average of $22.34. Sarepta Therapeutics, Inc. has a one year low of $10.41 and a one year high of $138.81.
- Pharma Fire Sale: 3 Stocks the RSI Says You Shouldn’t Ignore
Sarepta Therapeutics (NASDAQ:SRPT - Get Free Report) last announced its earnings results on Monday, November 3rd. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.02 by ($0.15). Sarepta Therapeutics had a negative return on equity of 1.03% and a negative net margin of 2.34%.The company had revenue of $399.36 million for the quarter, compared to analyst estimates of $331.51 million. During the same period last year, the firm earned $0.62 earnings per share. The firm's revenue for the quarter was down 14.5% on a year-over-year basis. As a group, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 2.67 EPS for the current fiscal year.
Sarepta Therapeutics Profile
(Free Report)Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.
Further Reading
- Five stocks we like better than Sarepta Therapeutics
- How Can Investors Benefit From After-Hours Trading
- Warner Bros. Sale Rumors Heat Up: What Investors Need to Know
- How to Buy Gold Stock and Invest in Gold
- From Science Project to Solvent: WeRide’s 761% Revenue Surge
- Utilities Stocks Explained – How and Why to Invest in Utilities
- Will the S&P 500 Rally in December? These 3 Signals Point to a Big Move Ahead
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in Sarepta Therapeutics Right Now?
Before you consider Sarepta Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Sarepta Therapeutics wasn't on the list.
While Sarepta Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
